GABA Metabolism Disorders and Succinic Semialdehyde Dehydrogenase Deficiency

γ-Aminobutyric acid (GABA) metabolism disorders encompass a spectrum of inherited defects in the enzymes responsible for the synthesis, degradation and recycling of the central nervous system’s principal inhibitory neurotransmitter. At the heart of this pathway lies succinic semialdehyde dehydrogenase (SSADH), a mitochondrial NAD⁺-dependent enzyme that oxidises succinic semialdehyde to succinate. In SSADH deficiency, mutations in the ALDH5A1 gene compromise enzyme function and lead to accumulation of GABA and its neuroactive by-product, γ-hydroxybutyric acid (GHB). Clinically, patients present in infancy or early childhood with hypotonia, developmental delay, autism spectrum features, movement disorders, sleep disturbance, epilepsy and psychiatric comorbidities. Pathophysiological studies reveal altered GABA receptor expression, disrupted synaptic inhibition, aberrant network oscillations and mitochondrial and redox imbalance. Diagnosis relies on biochemical detection of elevated GABA and GHB in body fluids, supported by molecular genetic testing. Despite no approved curative therapy, advances in disease modelling, biomarker identification and targeted approaches—including enzyme replacement, gene therapy and pharmacological chaperones—offer a translational pipeline toward effective interventions.

Research from Nature Portfolio

No recent Nature Portfolio content available.

GABA Metabolism Disorders and Succinic Semialdehyde Dehydrogenase Deficiency publication trend

The graph below shows the total number of articles in gaba metabolism disorders and succinic semialdehyde dehydrogenase deficiency across all publications each year (not limited to Nature Index journals).

Technical terms

γ-Aminobutyric acid (GABA): The primary inhibitory neurotransmitter in the mammalian central nervous system.

Succinic semialdehyde dehydrogenase (SSADH): A mitochondrial NAD⁺-dependent enzyme that catalyses the oxidation of succinic semialdehyde to succinate in the GABA catabolic pathway.

γ-Hydroxybutyric acid (GHB): A neuroactive metabolite formed from succinic semialdehyde via non-enzymatic or enzymatic routes, elevated in SSADH deficiency.

Induced pluripotent stem cell (iPSC): A somatic cell reprogrammed to an embryonic-like pluripotent state, capable of differentiating into disease-relevant cell types for modelling and therapy development.

Biomarker: A measurable indicator of biological or pathogenic processes, used here to track disease severity and therapeutic response in SSADH deficiency.

References

1. Understanding the Molecular Mechanisms of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD): Towards the Development of SSADH-Targeted Medicine. International Journal of Molecular Sciences (2022).
2. Functional Characterization of a Spectrum of Genetic Variants in a Family with Succinic Semialdehyde Dehydrogenase Deficiency. International Journal of Molecular Sciences (2024).
3. Clinical and molecular outcomes from the 5-Year natural history study of SSADH Deficiency, a model metabolic neurodevelopmental disorder. Journal of Neurodevelopmental Disorders (2024).
4. Reduced evoked cortical beta and gamma activity and neuronal synchronization in succinic semialdehyde dehydrogenase deficiency, a disorder of γ-aminobutyric acid metabolism. Brain Communications (2023).